IN CASE YOU MISSED IT: While American patients struggle to pay for their prescription drugs, Big Pharma is spending unprecedented amounts on efforts to prevent more affordable medications and treatments. Recent reporting from STAT News and Politico Pro found that in 2019, the trade group PhRMA spent over $28.9 million to lobby Congress. This influx of […]

Continue Reading

IN CASE YOU MISSED IT: On Friday, Roll Call published the below op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse. In this thought-provoking piece, Lane praises the bipartisan efforts of last year, notably those of Senators Richard Blumenthal (D-CT) and John Cornyn (R-TX), to rein in Big Pharma and lower prescription drug prices. […]

Continue Reading

IN CASE YOU MISSED IT: This morning, The Washington Post published a must-read analysis highlighting how AbbVie’s use of tactics like patent thickets have allowed them to continue raising the price of their drug AbbVie while also preventing more affordable generic alternatives from coming to market. Today’s analysis follows recent reporting from Axios that AbbVie has begun 2020 by raising the price […]

Continue Reading

IN CASE YOU MISSED IT: Axios reports that as of Friday, major pharmaceutical companies raised prices on over 440 drugs with an average price hike of 5 percent. Additional price increases are expected thought January. Through their use of manipulative tactics like evergreening and patent thicketing, Big Pharma has been able to extend their drug monopolies and prevent competitive drug […]

Continue Reading

IN CASE YOU MISSED IT: This morning, Politico Pro and STAT News published two must-read reports from the Campaign for Sustainable Rx Pricing and researchers at Brigham and Women’s Hospital that highlight the negative impact Big Pharma continues to have on the ability of American patients to access innovative treatments and affordable generic drug alternatives. Both reports found that large pharmaceutical […]

Continue Reading

IN CASE YOU MISSED IT: The Richmond Times Dispatch published the below op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse. In this must-read piece, Lane praises the bipartisan efforts of Representatives Abigail Spanberger (D-VA) and Tom Reed (R-NY) to rein in Big Pharma’s patent abuse. Their bill, the Biologic Patent Transparency Act, would bring much-needed transparency […]

Continue Reading

IN CASE YOU MISSED IT: This evening, The Wall Street Journal published a must-read report highlighting the harmful impact Big Pharma’s patent abuse is having on the ability of American patients to access more affordable generic drug alternatives.  According to this eye-opening report, despite a record number of generic drugs for cancer and other serious ailments, major drug companies […]

Continue Reading

Humira Revenue Up 9.6% In U.S., But Down Abroad Due To Biosimilar IN CASE YOU MISSED IT: The poster child for how big, brand-name drug companies abuse the patent system to keep drug prices high continues to reap the benefits from gaming the U.S. patent system. Yesterday, Inside Health Policy reported that Abbvie’s revenue from Humira […]

Continue Reading

Thanks Representatives Spanberger and Reed for introducing legislation to stop the big drug companies from using patent thickets to abuse the patent system and hurt patients WASHINGTON, D.C. – The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others released the following statement today in […]

Continue Reading

IN CASE YOU MISSED IT: A new report from the Kaiser Family Foundation (KFF) examines the rising cost of Medicare Part D drugs and found that Big Pharma has jacked up the price of key prescription drugs well above the rate of inflation between 2016 and 2017. Among the worst offenders, according to the KFF report, are drugs […]

Continue Reading